Total Reportable Segments was Purple Biotech’s largest segment in fiscal 2018, bringing in $2.00M of $4.00M (50%).
| Segments [axis] | FY 2017 | FY 2018 |
|---|---|---|
| Total Reportable Segments | $200.00K | $2.00M |
| Pain & Hypertension | $200.00K | $2.00M |
| Total | $400.00K | $4.00M |
Purple Biotech brought in $4.00M from its two segments in fiscal 2018, the year ended December 31, 2018. That was up 900.0% from $400.00K in fiscal 2017. Total Reportable Segments was the largest at $2.00M (50.0%), ahead of Pain & Hypertension at $2.00M (50.0%).
Compared with fiscal 2017, Total Reportable Segments grew 900.0% to $2.00M and Pain & Hypertension grew 900.0% to $2.00M.
Purple Biotech (PPBT) reports its revenue by segments [axis]. In fiscal 2018, Total Reportable Segments was its largest segment, bringing in $2.00M (50.0% of the total), followed by Pain & Hypertension at $2.00M (50.0%).
Total Reportable Segments was Purple Biotech's largest segment in fiscal 2018, bringing in $2.00M, or 50.0% of the $4.00M total across its two segments.
Total Reportable Segments grew faster than Pain & Hypertension in fiscal 2018, up 900.0% from $200.00K to $2.00M. Pain & Hypertension grew 900.0% to $2.00M.
Every figure comes from Purple Biotech's annual financial filings, as reported. Each line keeps the name Purple Biotech gives it, and years follow its fiscal calendar.
Purple Biotech's revenue by segments [axis] goes back to fiscal 2017, with figures through fiscal 2018. The latest four fiscal years are free to view, and the full history is available with a Business Quant subscription.